Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644400/
http://dx.doi.org/10.1007/s40278-020-84893-x
_version_ 1783606447566749696
collection PubMed
description
format Online
Article
Text
id pubmed-7644400
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-76444002020-11-06 Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports Reactions Weekly Case Report Springer International Publishing 2020-10-24 2020 /pmc/articles/PMC7644400/ http://dx.doi.org/10.1007/s40278-020-84893-x Text en © Springer International Publishing AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports
title Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports
title_full Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports
title_fullStr Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports
title_full_unstemmed Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports
title_short Enoxaparin-sodium/heparin/tocilizumab: Masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports
title_sort enoxaparin-sodium/heparin/tocilizumab: masking of inflammatory markers following off-label use, and lack of efficacy and: 5 case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644400/
http://dx.doi.org/10.1007/s40278-020-84893-x

Ejemplares similares